Amgen’s XGEVA Granted Marketing Authorization In European Union

Amgen said the European Commission has granted marketing authorization for XGEVA for the prevention of skeletal-related events in adults with bone metastases from solid tumors. This approval of XGEVA applies to all 27 EU member states.
RTTNews